LGND – Ligand Pharmaceuticals Incorporated
LGND — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
7.51
Margin Of Safety %
-22
Put/Call OI Ratio
0.95
EPS Next Q Diff
EPS Last/This Y
2.19
EPS This/Next Y
1.27
Price
205.3
Target Price
245.1
Analyst Recom
1
Performance Q
6.81
Upside
-37.5%
Beta
1.23
Ticker: LGND
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | LGND | 207.79 | 0.48 | 0.00 | 785 |
| 2026-03-10 | LGND | 211.84 | 0.47 | 0.05 | 793 |
| 2026-03-11 | LGND | 221.29 | 0.47 | 3.08 | 807 |
| 2026-03-12 | LGND | 211.83 | 0.85 | 0.41 | 1067 |
| 2026-03-13 | LGND | 211.48 | 0.85 | 0.41 | 1067 |
| 2026-03-17 | LGND | 210.75 | 0.91 | 0.25 | 1158 |
| 2026-03-18 | LGND | 209.34 | 0.91 | 0.38 | 1158 |
| 2026-03-19 | LGND | 210.76 | 0.91 | 0.18 | 1162 |
| 2026-03-20 | LGND | 205.25 | 0.90 | 0.20 | 1176 |
| 2026-03-23 | LGND | 200.23 | 1.04 | 0.89 | 967 |
| 2026-03-24 | LGND | 201.87 | 1.05 | 1.00 | 980 |
| 2026-03-25 | LGND | 204.73 | 1.05 | 0.00 | 986 |
| 2026-03-26 | LGND | 203.53 | 1.05 | 0.44 | 989 |
| 2026-03-27 | LGND | 195.51 | 1.04 | 999.99 | 1001 |
| 2026-03-30 | LGND | 192.79 | 1.04 | 1.33 | 1001 |
| 2026-03-31 | LGND | 199.29 | 1.05 | 0.07 | 1005 |
| 2026-04-01 | LGND | 199.69 | 1.05 | 0.07 | 1005 |
| 2026-04-02 | LGND | 200.02 | 1.02 | 1.60 | 1021 |
| 2026-04-06 | LGND | 203.52 | 1.01 | 0.13 | 1039 |
| 2026-04-07 | LGND | 205.12 | 0.95 | 2.00 | 1077 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | LGND | 207.88 | 38.2 | -32.1 | 8.52 |
| 2026-03-10 | LGND | 212.33 | 38.2 | -33.2 | 8.52 |
| 2026-03-11 | LGND | 221.43 | 38.2 | -30.1 | 8.52 |
| 2026-03-12 | LGND | 211.55 | 36.5 | -42.2 | 8.54 |
| 2026-03-13 | LGND | 202.92 | 36.5 | -41.7 | 8.54 |
| 2026-03-17 | LGND | 211.15 | 38.7 | -34.0 | 8.63 |
| 2026-03-18 | LGND | 209.63 | 38.7 | -37.1 | 8.63 |
| 2026-03-19 | LGND | 210.57 | 38.7 | -35.5 | 8.63 |
| 2026-03-20 | LGND | 204.51 | 38.7 | -40.2 | 8.63 |
| 2026-03-23 | LGND | 200.36 | 38.7 | -39.2 | 8.63 |
| 2026-03-24 | LGND | 201.91 | 38.7 | -34.7 | 8.63 |
| 2026-03-25 | LGND | 204.65 | 38.7 | -34.1 | 8.63 |
| 2026-03-26 | LGND | 203.68 | 38.7 | -36.8 | 8.63 |
| 2026-03-27 | LGND | 195.86 | 38.7 | -41.7 | 8.63 |
| 2026-03-30 | LGND | 192.66 | 38.7 | -38.1 | 8.63 |
| 2026-03-31 | LGND | 199.67 | 38.7 | -31.0 | 8.63 |
| 2026-04-01 | LGND | 199.82 | 38.7 | -35.8 | 8.63 |
| 2026-04-02 | LGND | 200.08 | 38.7 | -35.9 | 8.63 |
| 2026-04-06 | LGND | 203.32 | 38.7 | -33.8 | 8.63 |
| 2026-04-07 | LGND | 205.30 | 38.7 | -35.0 | 8.63 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | LGND | -8.09 | -0.41 | 7.06 |
| 2026-03-10 | LGND | -8.09 | -0.41 | 7.06 |
| 2026-03-11 | LGND | -8.09 | -0.41 | 7.10 |
| 2026-03-12 | LGND | -8.09 | -0.41 | 7.10 |
| 2026-03-13 | LGND | -8.09 | -0.41 | 7.10 |
| 2026-03-17 | LGND | -8.58 | -0.37 | 7.10 |
| 2026-03-18 | LGND | -8.58 | -0.37 | 7.10 |
| 2026-03-19 | LGND | -8.58 | -0.37 | 7.10 |
| 2026-03-20 | LGND | -8.58 | -0.37 | 7.10 |
| 2026-03-23 | LGND | -8.58 | -0.36 | 7.10 |
| 2026-03-24 | LGND | -8.58 | -0.36 | 7.10 |
| 2026-03-25 | LGND | -7.12 | -0.36 | 7.51 |
| 2026-03-26 | LGND | -7.12 | -0.36 | 7.51 |
| 2026-03-27 | LGND | -7.12 | -0.36 | 7.51 |
| 2026-03-30 | LGND | -7.12 | -0.37 | 7.51 |
| 2026-03-31 | LGND | -7.12 | -0.37 | 7.51 |
| 2026-04-01 | LGND | -7.47 | -0.37 | 7.51 |
| 2026-04-02 | LGND | -7.47 | -0.37 | 7.51 |
| 2026-04-06 | LGND | -8.29 | -0.76 | 7.51 |
| 2026-04-07 | LGND | -8.29 | -0.76 | 7.51 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.02
Avg. EPS Est. Current Quarter
1.84
Avg. EPS Est. Next Quarter
2.02
Insider Transactions
-8.29
Institutional Transactions
-0.76
Beta
1.23
Average Sales Estimate Current Quarter
59
Average Sales Estimate Next Quarter
63
Fair Value
159.29
Quality Score
96
Growth Score
76
Sentiment Score
68
Actual DrawDown %
9.9
Max Drawdown 5-Year %
-55.1
Target Price
245.1
P/E
35.15
Forward P/E
20.72
PEG
2.52
P/S
15.26
P/B
3.99
P/Free Cash Flow
83.62
EPS
5.83
Average EPS Est. Cur. Y
8.63
EPS Next Y. (Est.)
9.9
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
46.42
Relative Volume
0.72
Return on Equity vs Sector %
-15.2
Return on Equity vs Industry %
1.3
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.21
EBIT Estimation
-35
◆
LGND
Healthcare
$205.10
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
53.8
Range 1M
37.7%
Sup Dist
2.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
6.2%
EPS NY
14.7%
52W%
81.8%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+0.3% upside
Upside
+0.3%
Quality
96
MoS
-22%
Ligand Pharmaceuticals IncorporSector: Healthcare
Industry: Biotechnology
Employees: 47
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
LGND
Latest News
—
Caricamento notizie per LGND…
stock quote shares LGND – Ligand Pharmaceuticals Incorporated Stock Price stock today
news today LGND – Ligand Pharmaceuticals Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch LGND – Ligand Pharmaceuticals Incorporated yahoo finance google finance
stock history LGND – Ligand Pharmaceuticals Incorporated invest stock market
stock prices LGND premarket after hours
ticker LGND fair value insiders trading